Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03873324
Recruitment Status : Completed
First Posted : March 13, 2019
Last Update Posted : October 4, 2019
Sponsor:
Collaborator:
National Center for Research and Development, Poland
Information provided by (Responsible Party):
Celon Pharma SA

Brief Summary:
The planned study is to determine the safety and pharmacokinetic properties of CPL500036 compound after single and multiple (two weeks) administration in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: CPL500036 compound Drug: Placebo Phase 1

Detailed Description:

This is to be one-centre, single ascending dose and double-blind multiple ascending dose two part study of CPL500036 compound in healthy volunteers.

PART A is a single dose, open-label part with CPL500036 compound administered with dose escalation between cohorts.

PART B is a multiple, double-blind part with CPL500036 compound administered for 14 days with dose escalation between cohorts. Participants in this part are to be randomized to receive Investigational Medicinal Product (IMP) or placebo in 3:1 ratio.

Safety and pharmacokinetic properties of CPL500036 compound is to be determined following different doses in single oral IMP administration in PART A and different doses of IMP administered orally for two weeks in PART B.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Masking Description: Only PART B will be double-blind
Primary Purpose: Treatment
Official Title: One Centre Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL500036 Compound in Healthy Volunteers
Actual Study Start Date : December 20, 2018
Actual Primary Completion Date : September 16, 2019
Actual Study Completion Date : September 16, 2019

Arm Intervention/treatment
Experimental: CPL500036

PART A: 7 cohorts are to receive single dose of IMP. Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.

PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts.

Drug: CPL500036 compound
IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).

Placebo Comparator: Placebo
PART B: 2 Participants from 4 cohorts (total of 8 people) are to receive masking placebo capsules once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
Drug: Placebo
matching placebo capsules




Primary Outcome Measures :
  1. Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP. [ Time Frame: up to 24 hours after single administration of IMP in PART A and up to 24 hours after the last IMP administration in PART B ]
    MTD is defined as the highest dose for which no more than 1 of the 6 treated volunteers (less than 1/3) exhibits dose limiting toxicity (DLT).

  2. Safety and tolerability of IMP after single and multiple oral administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring. [ Time Frame: up to 14 days in PART A and up to 28 days in PART B of the study ]
    Participants are to be closely observed to assure maximal safety and to collect occurrence of all adverse events. All participants are to be monitored for clinically relevant changes in physical examination, vital signs, 12-lead ECG assessment and deviations from normal in clinical laboratory results (complete blood count, blood chemistry, urinalysis). To follow-up on all study participants telephone calls with a request for information regarding their health condition are to be made.


Secondary Outcome Measures :
  1. Cmax - maximum CPL500036 plasma concentration [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    The maximum concentration of the CPL500036 compound in plasma after IMP administration, obtained directly from the measured concentrations.

  2. AUC(0-72) - area under the plasma concentration - time curve from time 0 to 72h after IMP administration for CPL500036 [ Time Frame: up to 72 hours after administration of IMP in PART A ]
    The AUC(0-72) is a measure of total plasma exposure to the drug from time point zero to 72 hours after IMP administration.

  3. AUC(0-24) - area under the plasma concentration - time curve from time 0 to 24h after IMP administration for CPL500036 [ Time Frame: up to 24 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 and 14 in PART B ]
    The AUC(0-24) is a measure of total plasma exposure to the drug from time point zero to 24 hours after IMP administration.

  4. AUC(0-inf) - area under the plasma concentration - time curve from time 0 to infinity time for CPL500036 [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    The AUC(0-inf) is a measure of total plasma exposure to the drug from time point zero extrapolated to infinity.

  5. Tmax - time to reach maximum CPL500036 concentration [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    The Tmax is time to reach the maximum plasma concentration (Cmax), obtained directly from the actual sampling times.

  6. Kel - terminal elimination rate constant [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    Kel is to be estimated via linear regression of time versus log of concentration.

  7. T1/2 - The plasma elimination half-life for CPL500036 compound [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    T1/2 is to be calculated as 0.693/Kel.

  8. C (1,t) - CPL500036 concentration [ Time Frame: Determined on Day 2, 3, 4, 5, 6, 8, 9, 10, 11, 12 and 13 in PART B. ]
    The concentration of CPL500036 on day t before product administration.

  9. C (Tmax, t) - CPL500036 concentration [ Time Frame: Determined on Day 2, 3, 4, 5, 6, 8, 9, 10, 11, 12 and 13 in PART B. ]
    The concentration on day t measured on time Tmax which was calculated in PART A of the study.

  10. Amount of CPL500036 in each urine collection sample [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    It is to be calculated as CPL500036 concentration in urine sample times volume of urine collection.

  11. Ae - total amount of CPL500036 excreted in urine [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    Ae is to be calculated as asymptote of the plot of the cumulative amount of drug excreted after each collection interval plotted against the median of the collection interval.

  12. Clr - renal clearance [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    Clr is to be calculated by linear least squares regression analysis on semi-logarithmic transformed data (CLr = excretion rate/C).

  13. Excretion rate [ Time Frame: up to 72 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 7 in PART B and up to 72 hours after the last IMP administration on Day 14 in PART B ]
    Excretion rate calculated as = CLr/V x Dose x exp(-kt)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Caucasian female or male,
  • Age: 18-55 years old, inclusive,
  • Body-mass index (BMI): ≥18.5 kg/m^2 and <29.9 kg/m^2,
  • Non-smoker and nonuser of tobacco products for at least 3 months before screening,
  • Physical examination without any clinically relevant abnormality,
  • Laboratory values not clinically significant,
  • Volunteer (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception.

Exclusion Criteria:

  • Known allergy or hypersensitivity to other drugs similar in structure or class to CPL500036 compound, or to any excipients of the formulation,
  • Any known significant current or past acute or chronic disease or condition,
  • Participation in other clinical trial within 90 days preceding the screening,
  • Blood drawn within 30 days prior to inclusion to the study (more or equal to 300mL),
  • Positive results from pregnancy test for female participants,
  • Lactation in women participants,
  • Hypotension or hypertension in medical history,
  • Long QT interval syndrome or is under the treatment with antiarrhythmic drugs,
  • Narcotic, alcohol addiction or abuse,
  • Participant who adhere to a special diet (e.g. low calories, vegetarian).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03873324


Locations
Layout table for location information
Poland
BioResearch Group Sp. z o.o.
Kajetany, Nadarzyn, Poland, 05-830
Sponsors and Collaborators
Celon Pharma SA
National Center for Research and Development, Poland

Layout table for additonal information
Responsible Party: Celon Pharma SA
ClinicalTrials.gov Identifier: NCT03873324    
Other Study ID Numbers: 01PDE2018
First Posted: March 13, 2019    Key Record Dates
Last Update Posted: October 4, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No